Efficacy And Safety Evaluation Of Statin Therapy In Alzheimer’s Disease Patients: A Systematic Review And Meta-Analysis

Objective:To evaluate the efficacy and safety of statins in the treatment of AD.Methods:We searched the PubMed, Cochrane Library, EMBASE, OVID SP, and ProQuest databases to select double-blind, randomized controlled trials pertaining to statins given to patients with a diagnosis of AD. The meta-analysis used main outcomes such as Mini Mental State Examinationand Alzheimer’s Disease Assessment Scaleand secondary outcomes such as Dependence Scale, Activities of daily living scale, Neuropsychiatric Inventory, Clinical Global Impression of Change, and Alzheimer’s Disease Functional Assessment and Change Scale. We paid also attention to cerebral vascular disease risk factors mentioned. Safety measures included the standard reporting of any adverse events or laboratory abnormality.Results:Four studies (1127 participants) involving patients with a diagnosis of probable or possible AD were included. There was no significant difference between the statin and placebo groups regarding the main outcomes, secondary outcomes, or adverse events. Most of the studies tended to ignore or pay less attention to cerebral vascular disease risk factors (such as cigar, diabetes, hypertension.)Conclusion:Statins are well tolerated without unexpected adverse events. However, more research is needed to determine whether statins are effective for AD with vascular risk factors.